Morgan Stanley thinks that one of Sarepta Therapeutics ‘ drugs will receive accelerated approval from the Food and Drug Administration — creating a promising investing opportunity....
It’s time for investors to step away from card issuer Marqeta , according to JPMorgan. The firm lowered its rating for Marqeta to neutral from overweight....
Now is the time to buy Procter & Gamble , according to UBS, which says the company’s recent underperformance is “unwarranted.” Analyst Peter Grom upgraded the...
Investors searching for income were buoyed by the move higher in the 10-year Treasury yield, but there are also some other opportunities to bring in some...
It’s been hard to miss the buzz around a new class of obesity medications , but one big drawback to these therapies is that they require...
The stock market in March is looking grim, but certain “fortress” stocks can allow investors to play defense and beat the market. All the major indexes...
Just like the internet and the smartphone, artificial intelligence could dramatically alter the world we live in. And, Bank of America has some pointers for investors...
Maskot | Maskot | Getty Images The income and wealth gaps between people of color and white households are wide, but state-run retirement programs are attempting...
Stock pickers continued to shine in the volatile stock markets even after a strong year, and here are their highest conviction bets, according to Goldman Sachs....
Shares of Krystal Biotech can rally nearly 60% as use of its gene therapy to treat cases of herpes simplex virus mount, Goldman Sachs said. Analyst...
